Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-.kappa.B activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): ##STR00001## or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is -A.sub.1QA.sub.2-; Q is a bond, --C(.dbd.O)--, --OC(O)--, --C(.dbd.O)NR.sub.5--, --SO.sub.p--, --SO.sub.pNR.sub.5--, --C(O)O--, --NR.sub.5C(O)--, --OC(O)NR.sub.5--, --NR.sub.5C(O)O--, --S(O).sub.pNR.sub.5C(O)--, --C(O)NR.sub.5S(O).sub.p-- --NR.sub.5S(O).sub.p--, or --NR.sub.5C(.dbd.O)NR.sub.6--. Y is selected from hydrogen, C.sub.1-6alkyl, OR.sub.16, substituted C.sub.1-6alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A.sub.1 and A.sub.2 are independently selected from a bond, C.sub.1-3alkylene, or C.sub.1-3alkenylene, and R.sub.1-R.sub.11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.